Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer

Overview of attention for article published in Frontiers in oncology, February 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 8,602 followers.

RT @KrishanJethwa: A8-4 ❓ ICI timing Ongoing trials: 📌VOLTAGE-A: LC-CRT → Nivo → surgery 📌NCRT-PD-1-LARC: LC-CRT + Tislelizumab (anti-PD-…

RT @KrishanJethwa: A8-4 ❓ ICI timing Ongoing trials: 📌VOLTAGE-A: LC-CRT → Nivo → surgery 📌NCRT-PD-1-LARC: LC-CRT + Tislelizumab (anti-PD-…

RT @KrishanJethwa: A8-4 ❓ ICI timing Ongoing trials: 📌VOLTAGE-A: LC-CRT → Nivo → surgery 📌NCRT-PD-1-LARC: LC-CRT + Tislelizumab (anti-PD-…

RT @KrishanJethwa: A8-4 ❓ ICI timing Ongoing trials: 📌VOLTAGE-A: LC-CRT → Nivo → surgery 📌NCRT-PD-1-LARC: LC-CRT + Tislelizumab (anti-PD-…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.